Budesonide dry-powder inhalation - AstraZeneca
Alternative Names: Budesonide inhalation powder - AstraZeneca; Pulmicort Flexhaler; Pulmicort Turbohaler; Pulmicort TurbuhalerLatest Information Update: 02 May 2024
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; AstraZeneca KK
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma; Chronic obstructive pulmonary disease
- Discontinued COVID 2019 infections
Most Recent Events
- 28 Sep 2022 Discontinued - Phase-II for COVID-2019 infections (In the elderly, In adults) in United Kingdom (Inhalation) (AstraZeneca pipeline, September 2022)
- 02 Jun 2020 Phase-II clinical trials in COVID-2019 infections (In adults, In the elderly) in United Kingdom (Inhalation) (EudraCT2020-001889-10)
- 09 Aug 2006 Pulmicort Turbuhaler has been approved in Japan for the treatment of paediatric asthma